Melanie Nallicheri - EQRx CEO Director
| EQRXDelisted Stock | USD 1.83 0.13 6.63% |
Insider
Melanie Nallicheri is CEO Director of EQRx Inc
| Age | 54 |
| Phone | 617 315 2255 |
| Web | https://www.eqrx.com |
EQRx Management Efficiency
The company has return on total asset (ROA) of (0.1379) % which means that it has lost $0.1379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2025) %, meaning that it created substantial loss on money invested by shareholders. EQRx's management efficiency ratios could be used to measure how well EQRx manages its routine affairs as well as how well it operates its assets and liabilities.EQRx Inc currently holds 3.83 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. EQRx Inc has a current ratio of 28.18, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about EQRx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Prof MD | Lyell Immunopharma | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Kevin Dushney | Kymera Therapeutics | N/A | |
| Lauren White | C4 Therapeutics | N/A | |
| Dr MBA | Blueprint Medicines Corp | 55 | |
| David MD | Erasca Inc | 41 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| MD MBA | Pliant Therapeutics | 48 | |
| Mark Murcko | Relay Therapeutics | 65 | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| JD Esq | Black Diamond Therapeutics | 60 | |
| Fang PharmD | Black Diamond Therapeutics | 38 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Matthew JD | Arvinas | 49 | |
| Michael Diem | Century Therapeutics | 53 | |
| Hal MD | Pliant Therapeutics | N/A | |
| Jacquelyn JD | Cullinan Oncology LLC | 47 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 |
EQRx Inc Leadership Team
Elected by the shareholders, the EQRx's board of directors comprises two types of representatives: EQRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EQRx. The board's role is to monitor EQRx's management team and ensure that shareholders' interests are well served. EQRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EQRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Hoey, Chief Operations | ||
| Robert LLB, CoFounder Advisor | ||
| Alexis AM, Founder Directors | ||
| MAPP MD, CoFounder Advisor | ||
| Jamilu Rubin, Chief Officer | ||
| Sir CBE, CoFounder Advisor | ||
| Rona Anhalt, Chief Officer | ||
| Eric MD, Chief Exec | ||
| Melanie Nallicheri, CEO Director | ||
| Dina JD, Gen Sec |
EQRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EQRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (75.06 M) | |||
| Shares Outstanding | 487.7 M | |||
| Shares Owned By Insiders | 11.13 % | |||
| Shares Owned By Institutions | 68.24 % | |||
| Number Of Shares Shorted | 11.3 M | |||
| Price To Book | 1.00 X | |||
| EBITDA | (517.58 M) | |||
| Net Income | (169.09 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in EQRx Stock
If you are still planning to invest in EQRx Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EQRx's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |